Novavax releases first late-trial COVID-19 vaccine data; reports 90.4% efficacy, strong protection against variants

Novavax today announced phase 3 trial results for its COVID-19 vaccine, saying it provides 100% protection against moderate and severe disease, with a 90.4% overall efficacy. The phase 3 trial, which enrolled more than 29,000 participants across the U.S. and Mexico, also demonstrated the vaccine to be safe. Additionally, the Novavax vaccine maintained a 93% efficacy against COVID-19 variants that emerged between January and April of this year.
The vaccine uses recombinant nanoparticle technology to generate a coronavirus spike protein-generated antigen. The company says the vaccine is stored and stable at 2-8 degrees Celsius (about 35-46 degrees Fahrenheit), enabling the use of existing vaccine supply chain channels for distribution.
Related News Articles
Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The Department of Health and Human Services Sept. 18 announced it will take new actions to help improve care for individuals with long COVID. They include a…
Headline
The Food and Drug Administration has identified a Class I recall for Mo-Vis BVBA R-net Joysticks due to a firmware error that causes the wheelchair to ignore…
Headline
The Centers for Disease Control and Prevention is predicting a similar combined number of peak hospitalizations from COVID-19, the flu and respiratory…